A randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of OMN 6 in healthy subjects
Latest Information Update: 20 May 2025
At a glance
- Drugs OMN-6 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; First in man; Pharmacokinetics
Most Recent Events
- 22 Nov 2022 New trial record